946P - Sintilimab plus Lenvatinib as Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
信迪利单抗联合仑伐替尼作为不可切除肝细胞癌患者的转化治疗：一项前瞻性、非随机、开放标签、II期扩展队列研究
讲者：卢实春（北京）
947P - The Efficacy and Safety of Cadonilimab Combined with Lenvatinib for First-line Treatment of Advanced Hepatocellular Carcinoma: A Phase Ib/II Clinical Trial
卡度尼利单抗联合仑伐替尼一线治疗晚期肝细胞癌的疗效和安全性：Ib/II期临床试验
讲者：白莉（北京）
948P - Phase (Ph) 1/2 Study of Sitravatinib (Sitra) Alone or With Tislelizumab (TIS) in Advanced Hepatocellular Carcinoma (HCC) and Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
Sitravatinib （Sitra）单独或联合替雷利珠单抗（TIS）治疗晚期肝细胞癌（HCC）和胃/胃食管结合部癌（GC/GEJC）的1/2期（Ph）研究
讲者：李进（上海）
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
瑞戈非尼联合免疫治疗对比瑞戈非尼作为晚期肝细胞癌患者的二线治疗：一项多中心真实世界研究
讲者：李斌奎（广州）
950P - Phase II clinical study of sorafenib combined with tislelizumab in the treatment of first-line unresectable hepatocellular carcinoma and the predictive effect and correlation of CTC
索拉非尼联合替雷利珠单抗一线治疗不可切除肝癌的II期临床研究及CTC的预测作用及相关性
讲者：徐林（深圳）
951P - HAIC combined with anlotinib and TQB2450 as adjuvant therapy for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after hepatectomy: a single-centre, non-randomised, open clinical study
HAIC联合安罗替尼和TQB2450作为肝切除术后复发高风险肝细胞癌（HCC）患者的辅助治疗：一项单中心、非随机、开放的临床研究
讲者：张倜（上海）
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): a multicenter, single-armed, real-world study
仑伐替尼联合经动脉化疗栓塞（TACE）初始治疗晚期肝细胞癌的前瞻性、观察性试验（PROLONG）的有效性和安全性：一项多中心、单臂、真实世界的研究
讲者：邵国良（杭州）
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): a single-arm, phase 2 trial
替雷利珠单抗联合瑞戈非尼作为不可切除肝细胞癌（uHCC）的二线治疗：一项单臂2期试验
讲者：李忠超（济南）
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: a single arm, phase Ⅱ clinical trial
放疗联合替雷利珠单抗+安罗替尼一线治疗肝细胞癌：单臂Ⅱ期临床试验
讲者：Guishu Wu（泸州）
956P - Phase 2 study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
替雷利珠单抗联合干扰素-α辅助治疗和主动监测在微血管浸润的肝细胞癌患者中的2期研究
讲者：Yixiu Wang（上海）
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable HCC
Notable-HCC中期报告：新辅助PD-1和立体定向放射治疗可切除HCC患者的Ib期研究
讲者：Mingming Li（济南）
958P - Preliminary results of radiotherapy (RT) combined with sintilimab (Sin) and bevacizumab (Bev) in advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICIs): A prospective phase II study
放疗（RT）联合信迪利单抗（Sin）和贝伐珠单抗（Bev）治疗先前用免疫检查点抑制剂（ICIs）治疗的晚期肝细胞癌（HCC）的初步结果：一项前瞻性II期研究
讲者：薛军（武汉）
959P - Combination Therapy of Envafolimab and Suvemcitug in Patients with Hepatocellular Carcinoma (HCC): Results from a Phase II Clinical Trial
一项II期临床试验的结果：恩沃利单抗联合Suvemcitug治疗肝细胞癌（HCC）
讲者：马丽霞（长春）
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
SBRT通过激活MBD3降解介导的IL-6/JAK1-STAT3/PD-L1轴，提高免疫检查点抑制剂治疗肝细胞癌的疗效
讲者：闫伟伟（北京）
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
cfDNA甲基化、AFP和ctDNA突变在肝癌早期检测中的发现和验证：一项多中心前瞻性研究（ASCEND-Hep）
讲者：潘明新（广州）
965P - C14orf159 mutations are associated with shorter relapse-free survival and overall survival after liver transplantation in hepatocellular carcinoma patients meeting Hangzhou criteria
C14orf159突变与符合杭州标准的肝细胞癌患者肝移植后较短的无复发生存期和总生存期相关讲者：吴斌（青岛）968P - High Sensitivity Routine Blood Based Detection of HCC: An AI Model from 220k Patients
高灵敏度血常规检测肝癌：来自22万例患者的人工智能模型
讲者：Kin Nam Kwok（中国香港）
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
用大临床数据建立肝细胞癌（HCC）筛查新血常规成分特征
讲者：Ka Man Cheung（中国香港）
971P - Effect of Preoperative Frailty on Surgical Outcomes Following Hepatic Resection for Elderly Patients with Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study from China
术前虚弱对老年肝癌肝切除术后手术结果的影响：一项来自中国的多中心回顾性队列研究
讲者：樊钟琦（长春）
974P - The Barthel Index Predicts Surgical Textbook Outcomes Following Hepatectomy for Elderly Patients with Hepatocellular Carcinoma: A Multicenter Cohort Study from China
Barthel指数预测老年肝细胞癌患者肝切除术后的预后：一项来自中国的多中心队列研究
讲者：吕国悦（长春）
977P - Hepatic arterial infusion chemotherapy (HAIC) combined with Regorafenib and PD-1 inhibitors versus Regorafenib combined with PD-1 inhibitors for second-line treatment Hepatocellular carcinoma (HCC)
肝动脉输注化疗（HAIC）联合瑞戈非尼和PD-1抑制剂对比瑞戈非尼联合PD-1抑制剂二线治疗肝细胞癌（HCC）
讲者：Nan You（重庆）
982P - Transarterial Chemoembolization with Idarubicin versus Epirubicin for Hepatocellular Carcinoma: an Interim Analysis of a Multicentre, Randomized Controlled phase 3 trial
伊达比星对比表柔比星经动脉化疗栓塞治疗肝细胞癌：一项多中心随机对照3期试验的中期分析
讲者：章浙伟（杭州）
983P - Safety and Efficacy of Durvalumab plus Hepatic Artery Infusion Chemotherapy in HCC with Severe Portal Vein Tumor Thrombosis (Vp3/4) – the DurHope Study
度伐利尤单抗联合肝动脉灌注化疗治疗伴重度门静脉癌栓（Vp3/4）的肝细胞癌的安全性和有效性——DurHope研究
讲者：赵明（广州）
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
应用卷积神经网络模型预测不可切除肝癌肝动脉灌注化疗预后
讲者：Bing Quan（上海）
992P - Analyzing effectiveness and safety of standard-dose and low-dose bevacizumab combination with atezolizumab in patients with unresectable hepatocellular carcinoma: a multi-institutional study in Taiwan
标准剂量和低剂量贝伐珠单抗联合阿替利珠单抗治疗不可切除肝癌的有效性和安全性分析：台湾多机构研究
讲者：Yan-Lin Wang（中国台湾）
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
在一项多中心回顾性研究中，经动脉化疗栓塞联合多纳非尼加/不加PD-1抑制剂治疗最初不可切除肝细胞癌
讲者：段旭华（郑州）
997P - A practical risk classification of early recurrence and long term survival outcomes in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy: a decision tree analysis
伴微血管侵犯的肝细胞癌患者肝切除术后早期复发和长期生存结果的实用风险分类：决策树分析
讲者：麦荣云（南宁）
998P - Efficacy and Safety of Curative Hepatectomy after Conversion Therapies for Initial Unresectable Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Study
一项多中心倾向评分匹配研究：原发性不可切除肝细胞癌转化治疗后肝切除术的疗效和安全性
讲者：麦荣云（南宁）
999P - Donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II trial (DoHAICs study)
多纳非尼联合肝动脉灌注化疗（HAIC）和信迪利单抗治疗不可切除肝细胞癌（uHCC）：一项前瞻性单臂II期试验（DoHAICs研究）
讲者：张伟（天津）
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
替雷利珠单抗联合TKIs和FOLFOX4-HAIC转化治疗不可切除肝癌的疗效和安全性
讲者：Kai Tan（西安）
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: a retrospective, multi-center, real-world study
索拉非尼或仑伐替尼治疗晚期肝细胞癌失败后序贯瑞戈非尼的疗效比较：一项回顾性、多中心、真实世界研究
讲者：宋丹军（杭州）
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
阿替利珠单抗和贝伐珠单抗联合经动脉化疗栓塞和肝动脉灌注化疗治疗不可切除的高肿瘤负荷肝细胞癌
讲者：邱际亮（广州）
1008P - The safety and efficacy of PD-1 inhibitor (Sintilimab) combined with conventional transarterial chemoembolization (cTACE) for the initial treatment of the stage BCLC B hepatocellular carcinoma (HCC) beyond up-to-seven criteria
PD-1抑制剂（信迪利单抗）联合常规经动脉化疗栓塞（cTACE）初始治疗BCLC - B期up-to-seven标准的肝细胞癌（HCC）的安全性和有效性
讲者：王征（上海）
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
TACE联合仑伐替尼+信迪利单抗治疗肝癌合并门静脉癌栓的前瞻性研究
讲者：丁晓燕（北京）
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
新型的高选择性成纤维细胞生长因子受体（FGFR） 4抑制剂ABSK-011治疗FGF19过表达的晚期肝细胞癌（HCC）的首个在人体研究
讲者：Ann-Lii Cheng（中国台湾）
1013TiP - Refinement and Validation of a Comprehensive Clinical Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma: A Multicenter, Prospective Study Protocol
肝细胞癌早期检测的综合临床诊断模型（GAMAD）的改进和验证：一项多中心前瞻性研究方案
讲者：杨田（上海）
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
重组人5型腺病毒注射液联合经肝动脉栓塞序贯热消融治疗中高危复发性肝癌的疗效和安全性：一项前瞻性、开放标签、随机对照研究
讲者：李建军（北京）
1015TiP - A Prospective, Phase II Clinical Study of Tislelizumab monotherapy or in Combination with Lenvatinib for neoadjuvant Treatment of Resectable Hepatocellular Carcinoma
替雷利珠单抗单药或联合仑伐替尼用于可切除肝癌新辅助治疗的前瞻性II期临床研究
讲者：宋天强（天津）
91P - Erythroid Precursor-Differentiated Myeloid Cells promote Pulmonary metastasis in Hepatocellular Carcinoma
红系前分化骨髓细胞促进肝细胞癌肺转移
讲者：Wei-hang Zhu（广州）
945MO - AdvanTIG-206: Phase 2 Randomized Open-Label Study of Ociperlimab (OCI) + Tislelizumab (TIS) + BAT1706 (Bevacizumab Biosimilar) Versus TIS + BAT1706 in Patients (pts) With Advanced Hepatocellular Carcinoma (HCC)
讲者：Ming Mo Hou（中国台湾）
排名不分先后，如有遗漏或错误，欢迎广大读者朋友提醒及指正。